Airing February 25, the program will focus on understanding unmet needs in the management of early stage, estrogen receptor-positive breast cancer after patients have completed five years of treatment, and how the BCI molecular test can help inform decision-making beyond five years
--(BUSINESS WIRE)--bioTheranostics:
WHAT:
Lifetime’s “The Balancing Act” will feature a discussion about important developments in the management of early stage, estrogen receptor-positive (ER+) breast cancer, including understanding the risk of recurrence beyond year five, side-effects of long-term hormonal drugs, and how to create a more personalized treatment plan with the Breast Cancer IndexSM (BCI). BCI is a gene expression-based test that quantifies risk of breast cancer recurrence and predicts which patients have a high likelihood of benefitting from extended adjuvant endocrine therapy. BCI testing is performed on a patient’s tumor sample and provides valuable patient-specific information.
Help employers find you! Check out all the jobs and post your resume.
--(BUSINESS WIRE)--bioTheranostics:
WHAT:
Lifetime’s “The Balancing Act” will feature a discussion about important developments in the management of early stage, estrogen receptor-positive (ER+) breast cancer, including understanding the risk of recurrence beyond year five, side-effects of long-term hormonal drugs, and how to create a more personalized treatment plan with the Breast Cancer IndexSM (BCI). BCI is a gene expression-based test that quantifies risk of breast cancer recurrence and predicts which patients have a high likelihood of benefitting from extended adjuvant endocrine therapy. BCI testing is performed on a patient’s tumor sample and provides valuable patient-specific information.
Help employers find you! Check out all the jobs and post your resume.
